EA033238B1 - Новые производные тиенопиримидина в качестве ингибиторов nik - Google Patents

Новые производные тиенопиримидина в качестве ингибиторов nik

Info

Publication number
EA033238B1
EA033238B1 EA201790908A EA201790908A EA033238B1 EA 033238 B1 EA033238 B1 EA 033238B1 EA 201790908 A EA201790908 A EA 201790908A EA 201790908 A EA201790908 A EA 201790908A EA 033238 B1 EA033238 B1 EA 033238B1
Authority
EA
Eurasian Patent Office
Prior art keywords
thienopyrimidine derivatives
nik inhibitors
nik
inhibitors
new thienopyrimidine
Prior art date
Application number
EA201790908A
Other languages
English (en)
Other versions
EA201790908A1 (ru
Inventor
Джордж Хинд
Патриция Тисселли
Калум Маклеод
Самьюэль Эдвард Манн
Джон Гари Монтана
Стефен Колин Прайс
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201790908A1 publication Critical patent/EA201790908A1/ru
Publication of EA033238B1 publication Critical patent/EA033238B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

Изобретение относится к ингибиторам NF-κB-индуцирующей киназы (NIK, также известной как MAP3K14) формулы (I)в которой все заместители определны в формуле изобретения, применимым для лечения заболеваний, таких как рак. Настоящее изобретение также направлено на фармацевтические композиции, содержащие такие соединения, и на применение таких соединений или фармацевтических композиций для предупреждения или лечения заболеваний, связанных с NF-κB-индуцирующей киназой.
EA201790908A 2014-10-23 2015-10-22 Новые производные тиенопиримидина в качестве ингибиторов nik EA033238B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14190077 2014-10-23
PCT/EP2015/074430 WO2016062789A1 (en) 2014-10-23 2015-10-22 New thienopyrimidine derivatives as nik inhibitors

Publications (2)

Publication Number Publication Date
EA201790908A1 EA201790908A1 (ru) 2017-08-31
EA033238B1 true EA033238B1 (ru) 2019-09-30

Family

ID=51865981

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790908A EA033238B1 (ru) 2014-10-23 2015-10-22 Новые производные тиенопиримидина в качестве ингибиторов nik

Country Status (13)

Country Link
US (1) US10323045B2 (ru)
EP (1) EP3209670B1 (ru)
JP (1) JP6603713B2 (ru)
KR (1) KR102524622B1 (ru)
CN (1) CN107074881B (ru)
AU (1) AU2015334914B2 (ru)
BR (1) BR112017007715B1 (ru)
CA (1) CA2960567C (ru)
EA (1) EA033238B1 (ru)
ES (1) ES2704738T3 (ru)
IL (1) IL251779B (ru)
MX (1) MX371151B (ru)
WO (1) WO2016062789A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
CN107074881B (zh) 2014-10-23 2019-07-30 詹森药业有限公司 作为nik抑制剂的新的噻吩并嘧啶衍生物
WO2016062791A1 (en) 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New pyrazole derivatives as nik inhibitors
EP3209662B1 (en) 2014-10-23 2019-01-09 Janssen Pharmaceutica N.V. New compounds as nik inhibitors
ES2715104T3 (es) * 2014-10-23 2019-05-31 Janssen Pharmaceutica Nv Nuevos derivados de pirazolopirimidina como inhibidores de nik
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
KR20180094940A (ko) * 2015-12-02 2018-08-24 아스트레아 테라퓨틱스 엘엘씨 피페리디닐 노시셉틴 수용체 화합물
CN109810110B (zh) * 2017-11-22 2023-01-24 中国科学院上海药物研究所 一种具有2-氨基嘧啶结构的化合物，其制备方法和用途
EP3976597A1 (en) 2019-05-31 2022-04-06 Janssen Pharmaceutica NV Small molecule inhibitors of nf-kb inducing kinase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009158011A1 (en) * 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2012123522A1 (en) * 2011-03-16 2012-09-20 F. Hoffmann-La Roche Ag 6,5-heterocyclic propargylic alcohol compounds and uses therefor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX19185A (es) 1989-01-20 1993-12-01 Pfizer Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas.
JP2007534739A (ja) 2004-04-26 2007-11-29 ファイザー・インク ピロロピリジン誘導体及びｈｉｖインテグラーゼ酵素阻害剤としてのその使用
AR056786A1 (es) 2005-11-10 2007-10-24 Smithkline Beecham Corp Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
JP2011526931A (ja) 2008-07-03 2011-10-20 エグゼリクシス， インコーポレイテッド Ｃｄｋモジュレーター
WO2010042337A1 (en) 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
WO2014170421A1 (en) * 2013-04-19 2014-10-23 F. Hoffmann-La Roche Ag Serine/threonine kinase inhibitors
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
WO2016062791A1 (en) 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New pyrazole derivatives as nik inhibitors
EP3209662B1 (en) 2014-10-23 2019-01-09 Janssen Pharmaceutica N.V. New compounds as nik inhibitors
ES2715104T3 (es) 2014-10-23 2019-05-31 Janssen Pharmaceutica Nv Nuevos derivados de pirazolopirimidina como inhibidores de nik
CN107074881B (zh) 2014-10-23 2019-07-30 詹森药业有限公司 作为nik抑制剂的新的噻吩并嘧啶衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009158011A1 (en) * 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2012123522A1 (en) * 2011-03-16 2012-09-20 F. Hoffmann-La Roche Ag 6,5-heterocyclic propargylic alcohol compounds and uses therefor

Also Published As

Publication number Publication date
CN107074881B (zh) 2019-07-30
EP3209670A1 (en) 2017-08-30
US10323045B2 (en) 2019-06-18
AU2015334914A1 (en) 2017-03-30
ES2704738T3 (es) 2019-03-19
CA2960567C (en) 2023-03-07
CA2960567A1 (en) 2016-04-28
JP6603713B2 (ja) 2019-11-06
CN107074881A (zh) 2017-08-18
BR112017007715B1 (pt) 2023-04-11
KR20170066447A (ko) 2017-06-14
KR102524622B1 (ko) 2023-04-20
EA201790908A1 (ru) 2017-08-31
IL251779B (en) 2020-10-29
MX371151B (es) 2020-01-20
WO2016062789A1 (en) 2016-04-28
IL251779A0 (en) 2017-06-29
JP2017531675A (ja) 2017-10-26
BR112017007715A2 (pt) 2017-12-19
US20180298032A1 (en) 2018-10-18
AU2015334914B2 (en) 2019-09-19
EP3209670B1 (en) 2018-10-03
MX2017005285A (es) 2017-07-28

Similar Documents

Publication Publication Date Title
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
MX2022002579A (es) Compuestos de aminotiazol como inhibidores de c- kit.
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
PH12017502050A1 (en) Naphthyridine compounds as jak kinase inhibitors
MD4800B1 (ru) Соединения аминопиримидинила в качестве ингибиторов JAK
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
EA033236B1 (ru) Новые производные пиразола в качестве ингибиторов nik
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
EA033237B1 (ru) Новые производные пиразолопиримидина в качестве ингибиторов nik, фармацевтическая композиция и лекарственное средство, содержащее ее
MX2017005282A (es) Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik).
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
MX2018004879A (es) Nuevos derivados de piridona y su uso como inhibidores de quinasas.
PH12017501063A1 (en) Compounds for the treatment of cancer

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM